Ad Watchers: What Can Brands Say About Health Without Crossing the Line?

In this episode, the National Advertising Division (NAD) examines the rapid rise in pharma and health-related cases—now a significant and growing share of its docket. The conversation explores some of today’s most closely scrutinized issues, including GLP-1 and compounded drug claims, and a wide variety of health claims from eczema to plantar fasciitis, as well as strikethrough pricing and endorsement disclosures. This episode offers a timely look at how self-regulation is shaping industry practices through its wide-ranging guidance amidst increasing legal and regulatory pressure. Related Resources: NAD Case #7455: Galderma Laboratories, L.P. NAD Case #7489: Agendia, Inc. NAD Case #7534: Midi Health, Inc. NAD Case #7518: Fletcher Family Medical NAD Case #7430: The Good Feet Store Enjoyed this episode? Get caught up on past seasons of the Ad Watchers and subscribe to never miss an episode. The post Ad Watchers: What Can Brands Say About Health Without Crossing the Line? appeared first on BBB National Programs.